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Abstract: Background
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Methods
HIV-infected patients from two Canadian cohorts underwent transient elastography
(TE) examination and were classified as: 1) OcC (TE ≥13 kPa with no sign of cirrhosis,
including absence of thrombocytopenia and signs of advanced liver disease on
ultrasound or gastroscopy); 2) overt cirrhosis (OvC) (TE ≥13 kPa with signs of
cirrhosis); 3) non-cirrhotic patients (TE <13 kPa). Incidence and risk factors of liver-
related events were investigated through Kaplan-Meier and Cox regression analyses,
respectively. We estimated monitoring rates according to screening guidelines for
hepatocellular carcinoma (HCC) by OcC and OvC status.
Results
1092 HIV-infected patients (51% coinfected with hepatitis C virus) were included.
Prevalence of OcC and OvC at baseline was 2.7% and 10.7%, respectively. During a
median follow-up of 1.8 (interquartile range: 1.5– 2.8) years, the incidence of liver-
related events in non cirrhotics, OcC, and OvC was 3.4 (95% confidence interval [CI]:
1.2-7.3), 34 (95% CI: 6-104), and 37 (95% CI: 16.95-69.05) per 1000 person-years,
respectively. Baseline OcC (adjusted hazard ratio [aHR]: 7.1, 95% CI: 1.3-38) and OvC
(aHR: 8.5, 95% CI: 2.8-26) were independently associated with liver-related events.
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Monitoring rates for HCC were lower in patients with OcC (24%) compared to those
with OvC (40%).
Conclusions
HIV-infected patients with OcC have a high incidence of liver-related events. Greater
surveillance and earlier recognition with appropriate screening strategies is necessary
for improved outcomes.
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Short title: Occult Cirrhosis in HIV  
Summary: Occult cirrhosis affects 2.7% of HIV-infected patients, representing 20% of all 
cirrhosis cases. HIV-infected patients with occult cirrhosis have the same risk of liver-related 
events as those with clinically overt cirrhosis. HIV-infected patients with occult cirrhosis should 
receive greater surveillance for hepatocellular carcinoma.  
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Abstract 
Background 
Human immunodeficiency virus (HIV)-infected patients are at increased risk of liver-related 
mortality. The effect of occult cirrhosis (OcC), defined as preclinical compensated 
cirrhosis without any clinical findings, on liver-related events is unknown.  
Methods 
HIV-infected patients from two Canadian cohorts underwent transient elastography (TE) 
examination and were classified as: 1) OcC (TE ≥13 kPa with no sign of cirrhosis, including 
absence of thrombocytopenia and signs of advanced liver disease on ultrasound or gastroscopy); 
2) overt cirrhosis (OvC) (TE ≥13 kPa with signs of cirrhosis); 3) non-cirrhotic patients (TE <13 
kPa). Incidence and risk factors of liver-related events were investigated through Kaplan-Meier 
and Cox regression analyses, respectively. We estimated monitoring rates according to screening 
guidelines for hepatocellular carcinoma (HCC) by OcC and OvC status. 
Results 
1092 HIV-infected patients (51% coinfected with hepatitis C virus) were included. Prevalence of 
OcC and OvC at baseline was 2.7% and 10.7%, respectively. During a median follow-up of 1.8 
(interquartile range: 1.5– 2.8) years, the incidence of liver-related events in non cirrhotics, OcC, 
and OvC was 3.4 (95% confidence interval [CI]: 1.2-7.3), 34.0 (95% CI: 6.0-104.0), and 37.0 
(95% CI: 17.0-69.1) per 1000 person-years, respectively. Baseline OcC (adjusted hazard ratio 
[aHR]: 7.1, 95% CI: 1.3-38.0) and OvC (aHR: 8.5, 95% CI: 2.8-26.0) were independently 
associated with liver-related events. Monitoring rates for HCC were lower in patients with OcC 
(24%) compared to those with OvC (40%).   
 
 3 
Conclusions 
HIV-infected patients with OcC have a high incidence of liver-related events. Greater 
surveillance and earlier recognition with appropriate screening strategies is necessary for 
improved outcomes. 
 
Keywords: HIV, occult cirrhosis, transient elastography, liver-related events, HCC surveillance. 
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Introduction 
 
Liver disease is the leading cause of non-AIDS related deaths in people living with the human 
immunodeficiency virus (HIV)[1]. HIV-infected individuals have multiple risk factors for liver 
injury, including coinfections with hepatitis C (HCV) and B (HBV) viruses, metabolic conditions 
triggering non-alcoholic fatty liver disease (NAFLD), excessive alcohol intake, and antiretroviral 
therapy (ART) inducing hepatotoxicity[2, 3]. This hypothetical multi-hit process can then lead to 
cirrhosis, hepatocellular carcinoma (HCC), and complications associated with end-stage liver 
disease (ESLD) such as ascites, hepatic encephalopathy, and variceal bleeding[4]. Up to 63% of 
patients with liver disease are diagnosed with liver cirrhosis only at the first episode of hepatic 
decompensation[5]. Therefore, identifying patients with underlying liver cirrhosis is critical as 
surveillance for HCC and esophageal varices can be promptly initiated[6].  
 
A major obstacle to the diagnosis of cirrhosis at the preclinical stage, also known as occult 
cirrhosis (OcC), is the lack of any clinical, laboratory and imaging findings. Patients with OcC 
do not have thrombocytopenia and have no features consistent with cirrhosis on imaging. 
Nonetheless, OcC is identified in up to 12% of patients referred for transient elastography (TE) 
examination and it accounts for up to 37% of all cirrhosis cases[7, 8]. HIV-negative patients with 
OcC are at risk of developing ESLD events, but they receive suboptimal surveillance for HCC 
when compared to patients with clinically overt cirrhosis (OvC)[7-9]. 
 
Liver biopsy is the gold standard for the diagnosis of liver cirrhosis but it is invasive and prone to 
sampling errors leading to the misdiagnosis of cirrhosis[10-12]. As such, it is unpractical as a 
screening tool or for the follow-up of HIV-infected patients, where the prevalence of liver 
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disease is high[13]. The measurement of liver stiffness (LSM) by TE is a validated non-invasive 
method to diagnose liver cirrhosis, with a reported area under the curve of 0.94[14]. TE is 
superior to simple fibrosis biomarkers, including the aspartate to platelet ratio index (APRI) and 
the fibrosis-4 score (FIB-4), in HIV-infected patients infected[15-17].  
 
Thus far, the prevalence of OcC in HIV-infected patients and its impact on incident liver-related 
events has not been reported. We used data from two large clinical Canadian cohorts to fulfill the 
following aims: (i) determine the prevalence and associated factors of OcC diagnosed by TE; (ii) 
evaluate the incidence of liver-related events in patients with OcC; and (iii) investigate 
monitoring rates, according to guidelines, for screening of HCC in patients with OcC.    
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Patients and methods 
Study design and population 
We conducted a retrospective analysis of the Canadian Coinfection Cohort (CCC) and the LIVEr 
in HIV (LIVEHIV) studies[18, 19]. The CCC is a prospective cohort of patients co-infected with 
HIV and HCV enrolled at 18 centres across Canada where they are followed-up every 6 months 
since 2003. Centres participating in the FibroScan sub-study assessed LSM by TE examination 
every 6 months. The LIVEHIV Cohort is a prospective screening program for NAFLD and liver 
fibrosis established in 2013 at McGill University Health Centre (MUHC), Montreal, Canada. All 
patients underwent screening for liver disease with yearly TE examination. 
 
Ethics 
All participants provided informed written consent. The Research Ethics Board of the Research 
Institute of MUHC approved the study (code 14-182-BMD and 2006-1875), which was 
conducted according to the Declaration of Helsinki. 
 
Eligibility 
All consecutive HIV-infected adults aged ≥18 years were eligible. Patients in the CCC who were 
enrolled in centres not participating in the FibroScan sub-study were excluded. Patients with 
failure of TE examination or unreliable LSM were also excluded. 
 
Clinical and biological parameters 
Data collected included demographic information, HIV and medications history, body mass 
index (BMI), history of type 2 diabetes mellitus[20], liver biochemistries, hematological and 
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virological parameters. Alcohol intake was measured by the Alcohol Use Disorders 
Identification Test (AUDIT-C) questionnaire, with a score ≥4 for men and ≥3 for women 
considered as hazardous alcohol intake[21]. The following fibrosis biomarkers were computed: 
APRI (with a cut-off value ≥2 suggesting liver cirrhosis); FIB-4 (with a cut-off value ≥3.25 
suggesting advanced liver fibrosis)[17, 22]. Results of abdominal imaging and gastroscopies 
were recorded.  
 
TE examination 
The TE examination was performed in patients fasting for at least 3 hours. The standard M probe 
was used in all patients. The XL probe was used in cases of failure of TE with the M probe or if 
the BMI was greater than 30 kg/m2. The following criteria were applied to define the result of TE 
as reliable: at least 10 validated LSM, and an interquartile range (IQR) <30% of the median 
LSM[23]. Hepatic steatosis measurement by controlled attenuation parameter (CAP) was 
available in the LIVEHIV Cohort. Any grade hepatic steatosis (>5% of hepatocytes) was defined 
as CAP ≥288 decibels per meter (dB/m)[24]. 
 
Definition of study groups 
Patients were divided into four mutually exclusive subgroups. Patients with OcC had LSM ≥13 
kPa (10.1 kPa with the XL probe[25]) and no evidence of advanced liver disease or portal 
hypertension, namely absence of: thrombocytopenia (<140 x 109/L), cirrhosis on abdominal 
imaging (liver nodularity, enlarged caudate lobe, splenomegaly ≥14 cm), esophageal varices or 
hypertensive portal gastropathy on gastroscopy, and ascites. Patients with OvC had LSM ≥13 
kPa with evidence of advanced liver disease or portal hypertension, as listed above. Patients 
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classified as non-cirrhotic had LSM <13 kPa and no evidence of advanced liver disease or portal 
hypertension. Finally, patients classified as non-cirrhotic portal hypertension had LSM <13 kPa 
and evidence of advanced liver disease or portal hypertension. The 13 kPa cut-off has been 
chosen based on a meta-analysis[14]. 
 
Outcome measures 
Liver-related events were prospectively collected by means of a dedicated outcome measures 
form. Liver-related events included occurrence of de novo ascites, variceal bleeding or banding, 
spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy, HCC, liver 
transplantation, and death from liver-related causes. Screening interval for HCC was defined as 
receiving abdominal imaging at least every 12 months during the study period[26, 27]. 
 
Follow-up 
Patients were followed from their first TE examination (baseline, or time zero) until they had a 
liver-related event, died, withdrew consent, were lost to follow-up (no visits for more than 1.5 
years), or until administrative censoring (March 31, 2017 for the CCC and on January 14, 2017 
for the LIVEHIV cohort). Non liver-related deaths were censored. The decision to initiate 
surveillance for HCC was left to the treating physician. 
 
Statistical analysis 
Cross-sectional component 
The period prevalence was reported as the ratio of the total number of prevalent and incident 
cases to the total number of patients included in the study. The association between various risk 
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factors at inclusion and prevalent or incident OcC – among patients at risk for OcC - were 
assessed using a cross-sectional approach with unadjusted and adjusted logistic regression 
models. We reported results as adjusted odds ratios (aOR). Due to the cross-sectional nature of 
any such measured associations, we made no causal claims from these analyses. 
Longitudinal component 
Kaplan-Meier plots were used to show the cumulative incidences over time, as stratified by study 
group and coinfection status, using the log-rank test to test for differences between groups. The 
association between various risk factors and the incidence of de novo liver-related events were 
assessed with unadjusted and adjusted Cox proportional hazards models. Results were reported 
as adjusted hazard ratios (aHR) with 95% confidence intervals (CI). Finally, as an exploratory 
analysis, the proportion of patients – among those at risk for HCC – with adequate cirrhosis 
surveillance were reported descriptively and stratified by study group. The same analysis was 
stratified by source cohort and by HCV coinfection status. A two-sided level of significance of 
5% was used for all statistical inferences.  
Covariates 
All adjusted regression models included covariates that were determined a priori to be clinically 
important; this list was further restricted due to limited event counts. The following baseline 
covariates were chosen: age, sex, aboriginal ethnicity, hazardous alcohol intake in past year, 
BMI, diabetes in past year, lipid lowering therapy in past year, nadir CD4 count, detectable HIV 
RNA in past year, HCV RNA positive, HIV duration and ART duration. Where multiple models 
were estimated for the same outcome, the model with the best goodness-to-fit measure, based on 
the Akaike Information Criteria (AIC), was chosen. 
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Results 
After applying the inclusion and exclusion criteria, 1092 HIV-infected individuals were 
included, of whom 499 were HIV monoinfected, 556 were HIV/HCV coinfected and 37 were 
HIV/HBV coinfected (Figure 1). Failed or unreliable LSM comprised 7.0% of patients from the 
CCC and 5.8% of patients from the LIVEHIV cohort.  
 
Prevalence, incidence and factors associated with occult cirrhosis 
OcC and OvC represented 2.7% and 10.7% of our study population, respectively. OcC patients 
represented 19.9% of all patients with cirrhosis. The main characteristics by study group status at 
baseline are presented in Table 1. Figure 2 and Supplemental Table S1 report the distribution of 
study groups and the main characteristics by HCV and HBV coinfection status, respectively. The 
prevalence of OcC increased during the study period with 14 new cases, for an overall pooled 
period prevalence of 3.9%. Furthermore, over a median follow-up time of 1.8 (IQR: 1.5–2.8) 
years, the incidence rate of OcC was 10.0 (95% CI: 5.7–16.3) per 1000 person-years (PY). HIV 
monoinfected patients showed similar incidence of OcC compared to HCV coinfected patients. 
Conversely, those coinfected with HCV were more likely to develop OvC during follow-up 
compared to monoinfected patients (Figure 3a and 3b). Logistic regression identified HIV 
duration as an independent factor associated with the presence of OcC as compared to non-
cirrhotic patients (aOR 1.44, 95% CI: 1.18-1.77) (Table 2). We also observed a tendency for 
higher BMI to be a factor associated with OcC.  
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Incidence and risk factors of liver-related events 
The overall incidence of liver-related events was 8.6 (95% CI: 4.9–14.0) per 1000 PY, mainly 
driven by the occurrence of de novo ascites and HCC (Table 3). The incidence rate of liver-
related events was similar between patients with OcC and OvC (Table 3; Figure 3c). Conversely, 
non-cirrhotic patients had a very low incidence of liver-related events, while patients with non-
cirrhotic portal hypertension had an intermediate incidence. HCV coinfection showed a tendency 
to be associated with an increased incidence of liver-related events (Figure 3d). The presence of 
OcC and OvC at baseline, as well as longer HIV duration, were independent risk factors for 
liver-related events, with aHR of 7.12 (95% CI: 1.33-37.99), 8.5 (95% CI: 2.83-25.53), and 1.37 
(95% CI: 1.09-1.73) respectively (Table 4).  
 
Surveillance for HCC 
Patients with OcC received 0.70 (95% CI: 0.51-0.92) abdominal imaging visits per PY, 
compared to 0.87 (95% CI: 0.76-0.98) for those with OvC. Furthermore, the monitoring rate of 
HCC according to screening guidelines[26, 27] was 24% (95%: CI 10-44) and 40% (95%: CI 30-
49) in those with OcC and OvC, respectively (p=0.06, Supplemental Table S2). In patients with 
at least one HCC screening imaging, the annual rate of imaging was 0.97 (95% CI: 0.72-1.28) 
and 1.33 (95% CI: 1.16-1.51) per patient in those with OcC and OvC, respectively. One patient 
(HIV/HBV coinfected) with OcC developed HCC during the follow-up, accounting for an 
incidence of 15 per 1000 PY. At diagnosis, there were two lesions consistent with HCC, with the 
largest one measuring 6 cm and the smaller one 3 cm. This tumor was beyond any transplant 
criteria, including Milan Criteria, total tumor volume, Up-to-Seven, and UCSF criteria[28]. The 
patient was offered TACE and Sorafenib but declined. He died 7.8 months after the diagnosis. In 
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the OvC group, the 3 patients who developed HCC were HIV/HCV coinfected and were 
diagnosed at an earlier stage (single lesion ranging from 1.7 to 3.2 cm). They were offered 
transarterial chemoembolization (n=1) or liver transplant (n=2) and are still alive. 
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Discussion 
In this well-characterized clinical cohort, we showed that OcC is a frequent occurrence, 
representing nearly 20% of all patients with liver cirrhosis in HIV-infected individuals. We also 
showed that liver-related events had similar incidence rates in HIV-infected patients with OcC 
and OvC, rendering essential for the HIV clinician to be aware of this clinical entity. Finally, 
patients with OcC do not receive screening at recommended intervals for detection of important 
ESLD complications, specifically HCC, which may result in a late diagnosis.  
 
Until recently, the description of a liver as “cirrhotic” was sufficient to define patients’ 
prognosis. Garcia-Tsao et al suggested that cirrhosis is rather a dynamic condition encompassing 
a more complex clinicopathological spectrum[29]. Given the lack of any clinical sign, patients at 
the preclinical stage of compensated cirrhosis represent a diagnostic challenge for clinicians, and 
often remain undiagnosed. The diagnosis of OcC based on LSM and the absence of clinical signs 
has previously been shown, in different patient populations, to be an indicator of poor 
prognosis[7, 9]. Individuals living with HIV are known to be at increased risk of liver cirrhosis 
and ESLD[1]. Our study is the first to report on the prevalence of OcC and its impact on liver-
related events in HIV-infected patients.  
 
In our large combined cohort of 1092 HIV-infected patients, OcC was found in 2.7% of cases, 
prevalence similar to that reported in other populations[7, 9]. Although seemingly comprising 
only a small proportion of patients at baseline TE, the prevalence of OcC increased to 3.9% 
during the follow-up period, with an annual incidence rate of 10 per 1000 PY. These changes in 
LSM may herald a poor prognosis, as reported in other patient populations[30-32].   
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The only independent factor associated with OcC at baseline vs. non-cirrhotic subgroup was 
longer duration of HIV infection, which is a proxy for exposure to multiple hepatotoxic hits[18]. 
Interestingly, HCV coinfection was not associated with an increased prevalence or incidence of 
OcC, but rather with the development of OvC. This could be explained by either a faster 
progression of HCV coinfected patients from earlier stage of liver disease to OvC[33] or because 
they are more frequently monitored with TE, and thus diagnosed more often. Higher BMI had a 
trend in being an independent risk factor for OcC, thus confirming the emerging concern around 
NAFLD in HIV-infected patients[18, 34]. Accordingly, hepatic steatosis diagnosed by CAP had 
the highest frequency in the OcC group (27%). Taken together, our findings suggest that 
clinicians should suspect OcC in patients with longer HIV infection and higher BMI even in 
absence of any sign of liver cirrhosis. Moreover, screening for liver cirrhosis should not be 
limited to HIV patients coinfected with HCV, as multiple risk factors may still be driving 
progressive liver fibrosis and we would miss important opportunities to prevent liver 
decompensation. 
 
Patients with OcC were more likely to develop a liver-related event when compared to patients 
without cirrhosis, with a 10 times higher incidence rate. On the other hand, the incidence of a 
liver-related event was similar between those with OcC and OvC. Our findings are similar to a 
previous study by Merchante and colleagues where patients with cirrhosis had an incidence of 
hepatic decompensation of 46 per 1000 person-years[32]. Similarly, Macias et al reported that 
patients with LSM below 14.6 kPa have a lower risk of decompensation[35]. However, these 
studies did not differentiate between patients with and without clinical evidence of liver 
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cirrhosis. Furthermore, they only included HIV/HCV coinfected cases, so information about 
dynamics and evolution of OcC in HIV monoinfected patients was missing. In our study, the 
diagnosis of OcC at baseline was independently associated with the development of liver-related 
events. These findings underline that HIV-infected patients with OcC, whether or not HCV 
coinfected, constitute a group of patients beyond the traditional subset of patients with OvC, who 
are at high-risk of liver-related events. 
 
Despite a high incidence of liver-related events, our cohort study shows that HIV-infected 
patients with OcC appear to be less frequently monitored with abdominal ultrasounds when 
compared to those with OvC. Guidelines advocate regular screening ultrasounds for HCC in 
patients with a known diagnosis of cirrhosis and in HBV/HIV coinfected patients. Adherence to 
HCC screening guidelines remains low in HIV-infected patients, with reported rates between 
20% and 35%[36, 37]. Under recognition of cirrhosis at its preclinical stage, lack of awareness of 
liver-related complications, and potential patient-related factors may explain this low 
adherence[36]. Importantly, HIV-infected patients with HCC have a shorter expected survival 
when compared to HIV negative[38, 39]. Our findings suggest that HIV-infected patients should 
be screened for OcC with non-invasive diagnostic tools, such as TE, and that those with OcC 
should be considered for HCC surveillance.  
 
Our study has several strengths. To our knowledge, it is the first study characterizing risk factors 
and dynamics of liver cirrhosis in its preclinical stage in HIV-infected patients. It relies on two 
prospectively maintained large cohorts of consecutive individuals living with HIV. We employed 
an accurate and validated non-invasive tool to diagnose liver cirrhosis[13, 40]. We wish to 
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acknowledge several limitations of our study. First, although we included a large number of 
patients, the follow-up period was relatively short. We observed a limited number of clinical 
outcomes and thus our estimates of incidence rates are imprecise. However, our findings showed 
that OcC patients behave as those with OvC in case of HIV infection. Second, because a cross-
sectional approach was used to determine factors associated with OcC, no inferential conclusions 
can be derived. However, these associated factors could help identify who might be prioritized 
for screening. Third, we did not have data about the indication for ultrasound, which could have 
been performed for reasons other than HCC screening. Fourth, there is a potential for competing 
risk from death from other causes. Fifth, liver biopsy was not available in our study. However, 
we validated our findings longitudinally by demonstrating that OcC group had worse clinical 
outcomes than the non-cirrhotic group. Using liver biopsy in our cohort of more than 1,000 
patients would not have been feasible. 
 
In conclusion, OcC accounts for 1 in 5 cases of cirrhosis in HIV-infected patients. These 
patients, whether HCV coinfected or not, constitute a high-risk group prone to liver-related 
events. We advocate that HIV-infected patients with OcC should receive surveillance for HCC to 
the same degree as patients with OvC. Screening for cirrhosis with point of care non-invasive 
diagnostic tools, such as TE, should be considered in HIV-infected patients, especially in case of 
long duration of HIV infection and higher BMI. 
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Table 1. Patient characteristics at baseline by study group status (n=1092). 
 
 
  
Non-cirrhotic 
(n=795) 
Occult cirrhosis 
(n=29) 
Overt cirrhosis 
(n=117) 
Non-cirrhotic 
portal 
hypertension 
(n=151) 
p 
Follow-up time 
(years) 
1.53  
(1.44-2.60) 
2.62  
(1.50-2.96) 
2.48  
(1.55-3.09) 
2.36  
(1.50-2.96) 
<0.001 
Age (years) 
48.7  
(40.7-54.8) 
50.5  
(45.2-54.8) 
52.6  
(48.1-57.5) 
51.5  
(45.6-56.6) 
<0.001 
Female (%) 206 (26) 8 (28) 25 (21) 37 (25) 0.742 
MSM (%) 258 (32) 14 (48) 51 (44) 54 (36) 0.04 
Ethnicity (%) 
Caucasian 339 (43) 15 (52) 88 (75) 97 (64) <0.001 
Black 166 (21) 3 (10) 9 (8) 15 (10) <0.001 
Latino 58 (7) 1 (3) 0 6 (4) 0.01 
Asian 20 (3) 3 (10) 3 (3) 3 (2) 0.073 
Indigenous 125 (16) 5 (17) 12 (10) 17 (11) 0.251 
Unknown 93 (12) 3 (10) 5 (4) 15 (10) 0.111 
BMI (Kg/m2) 
25.1  
(22.7-28.4) 
26.8  
(24.1-30.7) 
25.2  
(22.1-27.5) 
24.3  
(21.0-26.8) 
0.005 
Obesity 
(BMI>30) (%) 
106 (13) 6 (21) 15 (13) 12 (8) 0.17 
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Hazardous 
alcohol intake 
(%) 
104 (13) 4 (14) 23 (20) 33 (22) 0.02 
Active tobacco 
smoker (%) 
266 (33) 11 (38) 62 (53) 80 (53) <0.001 
Active IDU (%) 197 (25) 5 (17) 44 (38) 64 (42) <0.001 
HIV duration 
(years) 
11 (6-19) 19 (14-26) 19 (12-24) 16 (9-22) <0.001 
CD4 nadir 
(cells/L) 
209 (99-350) 121 (28-290) 153 (89-277) 180 (105-302) 
0.039 
CD4 cell count 
(cells/L) 
514 (340-720) 526 (416-673) 406 (272-606) 536 (367-719) 0.004 
HIV viral load in 
log10 (units) 
1.59  
(1.59-1.63) 
1.59  
(1.59-1.60) 
1.59  
(1.59-1.59) 
1.59  
(1.59-1.59) 
0.434 
Undetectable 
HIV viral load  
(≤ 50 copies) (%) 
590 (74) 22 (76) 90 (77) 118 (78) 0.949 
Duration of ART 
(years) 
7.2 (3.2-12.9) 11.4 (4.6-15.8) 11.1 (5.9-17.2) 9.0 (4.8-16.2) <0.001 
Current ART 
used (%) 
655 (82) 20 (69) 103 (88) 134 (89) 0.019 
NRTI 617 (78) 19 (66) 97 (83) 123 (81) 0.147 
NNRTI 212 (27) 6 (21) 30 (26) 31 (21) 0.410 
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PI 329 (41) 10 (34) 49 (42) 71 (47) 0.501 
Integrase 
inhibitors 
237 (30) 8 (28) 44 (38) 
59 (39) 0.066 
Other 59 (7) 1 (3) 7 (6) 11 (7) 0.818 
Exposure to 
Didanosine  
(mean years±SD) 
0.26 ± 1.58 0.32 ± 1.17 0.26 ± 1.55 0.37 ±1.49 0.648 
Exposure to 
Stavudine  
(mean years±SD) 
0.56 ± 1.95 0.29 ± 0.95 0.23 ± 1.09 0.69 ± 2.26 0.266 
HCV coinfection 
(%) 
337 (42) 18 (62) 99 (85) 102 (68) <0.001 
HBsAg pos (%) 16 (2) 1 (3) 6 (5) 14 (9) <0.001 
Hypertension 
(%) 
125 (16) 9 (31) 25 (21) 24 (16) 0.082 
Diabetes (%) 145 (18) 7 (24) 27 (23) 31 (21) 0.526 
INR 
1.00 (0.93-1.03) 1.02 (1.00-1.13) 1.09 (1.00-1.15) 
1.00 (0.98-1.07) <0.001 
Platelets (109/L) 212 (182-259) 208 (171-241) 130 (98.8-189) 133 (113-180) <0.001 
Total cholesterol 
(mmol/L) 
4.5 (3.8-5.2) 3.8 (3.5-4.5) 3.9 (3.1-4.4) 4.1 (3.6-4.9) <0.001 
LDL cholesterol 
(mmol/L) 
2.6 (2.0-3.2) 1.7 (1.2-2.7) 2.0 (1.5-2.5) 2.3 (1.8-2.8) <0.001 
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HDL cholesterol 
(mmol/L) 
1.2 (1.0-1.4) 0.9 (0.7-1.2) 1.1 (0.9-1.3) 1.1 (0.9-1.3) <0.001 
Triglycerides 
(mmol/L) 
1.3 (0.9-2.0) 1.7 (1.1-2.5) 1.3 (0.9-1.7) 1.3 (0.9-2.1) 0.300 
Creatinine 
(µmol/L) 
80 (68-93) 78.0 (66.0-104) 82.5 (68.8-94.8) 77 (68-89) 0.794 
Insulin (pmol/L) 75 (47-137) 148 (112-262) 92 (60-190) 66 (42-145) <0.001 
ALT (IU/L) 29 (20-47) 41 (29-84) 45 (29-79) 33 (20-52) <0.001 
AST (IU/L) 28 (21-39) 46 (29-55.2) 51 (32-80) 32 (23-48) <0.001 
Total bilirubin 
(µmol/L) 
10 (7-15) 12 (9.35-18.5) 14 (9-20.1) 11 (8-17) <0.001 
Albumin (g/L) 41 (39-44) 41 (37-44) 40.5 (36.2-43) 42 (39-45) 0.007 
APRI >2 (%) 13 (2) 4 (14) 33 (28) 10 (7) <0.001 
FIB-4 >3.25 (%) 16 (2) 4 (14) 47 (40) 27 (18) <0.001 
CAP (dB/m) 228 (192-259) 248 (212-292) 208 (172-237) 218 (174-259) 0.006 
CAP >288 (%) 82/558 (15) 6/22 (27) 5/56 (9) 16/97 (16) 0.217 
 
Legend: Continuous variables are expressed as median (IQR) and categorical variables are 
expressed as frequencies (%), unless otherwise specified. For the three-way comparison of 
patients with no cirrhosis, occult cirrhosis, or overt cirrhosis, p-values were computed using a 
Fisher’s exact test for dichotomous variables, a chi-squared test for categorical variables, and a 
Kruskal-Wallis test for continuous variables, and are considered significant when below 0.05. 
CAP was available in 733 out of 1092 patients. Abbreviations; ALT, alanine aminotransferase; 
 26 
APRI, AST-to-Platelet Ratio Index; ART, antiretroviral therapy; AST, aspartate 
aminotransferase; BMI, body mass index; HIV, human immunodeficiency virus; HDL, high-
density lipoprotein cholesterol; IDU, injection drug use; IU, international units; LDL, low-
density lipoprotein cholesterol; MSM, men who have sex with men; NNRTI, non-nucleoside 
reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; PI, Protease 
Inhibitors; SD, standard deviation.  
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Table 2. Factors associated with occult cirrhosis by logistic regression analysis. 
 
Variable 
OR  
(95% CI) 
Model 1 
aOR (95% CI) 
Model 2 
aOR (95% CI) 
Age (per 10 years) 1.36 (0.99-1.88) 1.45 (1.03-2.06) - 
Female sex (yes vs no) 0.97 (0.42-2.03) 1.07 (0.46-2.28) 1.19 (0.51-2.57) 
Indigenous ethnicity (yes vs no) 0.51 (0.12-1.46) - - 
Hazardous alcohol intake in 
past year (yes vs no) 
1.04 (0.35-2.51) - - 
BMI (per 5 units) 1.19 (0.9-1.5) 1.20 (0.92-1.52) 1.25 (0.95-1.58) 
Diabetes in past year (yes vs no) 1.67 (0.73-3.52) - - 
Lipid lowering therapy in past 
year (yes vs no) 
1.12 (0.41-2.57) - - 
Nadir CD4 count (per 100 cells) 0.94 (0.77-1.12) - - 
Detectable HIVRNA in past year 
(yes vs no) 
0.69 (0.2-1.79) - - 
HCV coinfection (yes vs no) 1.21 (0.61-2.36) 1.46 (0.72-2.94) 1.30 (0.65-2.56) 
HIV duration (per 5 years) 1.39 (1.15-1.69) - 1.44 (1.18-1.77) 
ART duration (per 5 years) 1.14 (0.88-1.47) - - 
AIC 296.55 288.33 
 
Legend: Occult cirrhosis patients (n=29) are compared to non-cirrhotic patients (n=795). Odds 
ratios (OR) and 95% confidence interval (CI) are presented for each variable in the unadjusted 
and adjusted analysis. AIC, Akaike information criterion; aOR, adjusted odds ratio; ART, 
 28 
antiretroviral therapy; BMI, body mass index; HCV, hepatitis C virus; HIV, human 
immunodeficiency virus. 
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Table 3. Incidence rate of liver-related events during follow-up.  
 
 
  
  
Non-cirrhotic 
(n=795) 
Occult cirrhosis 
(n=29) 
Overt cirrhosis 
(n=117) 
Non-cirrhotic portal 
hypertension 
(n=151) 
Cases 
Incidence 
rate  
(95% CI) Cases 
Incidence 
rate  
(95% CI) Cases 
Incidence 
rate  
(95% CI) 
 
 
Cases 
Incidence 
rate  
(95% CI) 
Any liver event 
5 
3.4  
(1.2-7.3) 
2 
34.0 
(6.0-104.0) 
8 
37.0  
(17.0-69.1) 
4 
12.7  
(3.94-29.5) 
Ascites 
1 
0.68  
(0.04-2.97) 
2 
33.34  
(5.54-102.89) 
5 
21.48  
(7.7-46.16) 
3 
9.51  
(2.37-24.66) 
Varices with 
bleeding or 
banding 
2 
1.35  
(0.22-4.16) 
0 - 0 - 1 
3.08  
(0.18-13.55) 
Spontaneous 
bacterial 
peritonitis 
1 
0.67  
(0.04-2.96) 
0 - 1 
3.83  
(0.22-16.85) 
0 - 
Hepatic 
encephalopathy 
0 - 0 - 3 
11.56  
(2.87-29.97) 
0 - 
Hepatorenal 
syndrome 
0 - 0 - 1 
3.71  
(0.21-16.32) 
0 - 
HCC 
1 
0.67  
(0.04-2.96) 
1 
15.49  
(0.88-68.13) 
3 
11.61 
 (2.89-30.08) 
1 
3.08  
(0.18-13.55) 
ESLD-related 
death 
0 - 1 
15.33  
(0.87-67.44) 
1 
3.71  
(0.21-16.31) 
0 - 
 
Legend: Incidence rates are presented as 1000 person-years (PY) with 95% confidence interval 
(CI). ESLD, end stage liver disease; HCC, hepatocellular carcinoma.   
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Table 4. Risk factors associated with any liver event by Cox proportional hazards regression analysis. 
 
Variable HR (95% CI) aHR (95% CI) 
Occult cirrhosis at baseline (yes vs no) 4.45 (0.96-20.62) 7.12 (1.33-37.99) 
Overt cirrhosis at baseline (yes vs no) 8.49 (3.03-23.75) 8.5 (2.83-25.53) 
Age (per year) 1.04 (1.01-1.07) - 
Female sex (yes vs no) 0.79 (0.22-2.78) - 
Hazardous alcohol intake in the past year  
(yes vs no) 
2.97 (1.05-8.39) - 
BMI ≥ 30 in past year (yes vs no) 0.95 (0.22-4.17) - 
Diabetes in past year (yes vs no) 1.92 (0.61-5.98) - 
Lipid lowering therapy in past year (yes vs no) 0.46 (0.06-3.47) - 
Nadir CD4 count (per 100 cells) 0.79 (0.59-1.06) - 
Detectable HIVRNA in past year (yes vs no) 1.71 (0.54-5.38) 1.55 (0.51-4.67) 
HCV coinfection (yes vs no) 1.83 (0.65-5.18) - 
HIV duration (per 5 years) 1.55 (1.23-1.96) 1.37 (1.09-1.73) 
ART duration (per 5 years) 1.63 (1.14-2.32) - 
 
Legend: Hazard ratios (HR) and 95% confidence interval (CI) are presented for each variable in 
the unadjusted and adjusted analysis. aHR, adjusted hazard ratio; ART, antiretroviral therapy; 
BMI, body mass index; HCV, hepatitis C virus; HIV, human immunodeficiency virus.  
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Figure legends 
 
Figure 1. Flow chart displaying the selection of study participants, stratified by study cohort. [1] 
Administrative censoring was applied on March 31, 2017 for the CCC and on January 14, 2017 
for the LIVEHIV cohort. [2] Liver stiffness measures by TE were considered reliable if the ratio 
of the IQR over the median of the 10 measures was no more than 30%. 
Figure 2. Distribution of study groups (OvC, OcC, non-cirrhotic, non-cirrhotic portal 
hypertension) according to HCV and HBV coinfection status. 
Figure 3. Survival curves of: (a) incidence of OcC by HCV coinfection status; (b) incidence of 
OvC by HCV coinfection status; (c) probability of liver-related events by study group category; 
(d) probability of liver-related events by HCV coinfection category. The p-values refer to log-
rank test. 
Figure (.tif and .eps files only) Click here to access/download;Figure (.tif and .eps files only);Figure 1.tiff
Figure (.tif and .eps files only) Click here to access/download;Figure (.tif and .eps files only);Figure2.tiff
Figure (.tif and .eps files only) Click here to access/download;Figure (.tif and .eps files only);Figure 3a.tiff
Figure (.tif and .eps files only) Click here to access/download;Figure (.tif and .eps files only);Figure 3b.tiff
Figure (.tif and .eps files only) Click here to access/download;Figure (.tif and .eps files only);Figure 3c.tiff
Figure (.tif and .eps files only) Click here to access/download;Figure (.tif and .eps files only);Figure3d.tiff
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Supplemental Table S1. Patient characteristics at baseline by HCV and HBV coinfection status 
(n=1092). 
 
  
HIV monoinfected 
(n=499) 
HIV/HCV coinfected 
(n=556) 
HIV/HBV coinfected 
(n=37) 
p 
Total follow-up time 
(years) 
1.50 (1.43-2.17) 2.36 (1.50-3.02) 
2.14 (1.45-3.07) <0.001 
Age (years) 50.8 (42.9-57.5) 48.7 (41.6-54.2) 54.1 (49.0-61.0) <0.001 
Female (%) 119 (24) 152 (27) 3 (8.1) 0.204 
MSM (%) 175 (35) 184 (33) 26 (70) 0.516 
Ethnicity (%) 
Caucasian 166 (33) 350 (63) 20 (54) <0.001 
Black 158 (32) 29 (5) (36) <0.001 
Latino 53 (11) 11 (2) 0 <0.001 
Asian 16 (3) 12 (2) 2 (6) 0.339 
Indigenous 1 (0) 156 (28) 0 <0.001 
Unknown 105 (21) 7 (1) 1 (3) <0.001 
BMI (Kg/m2) 25.6 (23.3-29.0) 24.6 (21.8-27.8) 25.8 (21.6-28.9) <0.001 
Obesity (BMI>30) (%) 81 (16) 55 (10) 2 (6) 0.002 
Hazardous alcohol 
intake (%) 
39 (8) 119 (21) 3 (8) <0.001 
Active tobacco  
smoker (%) 
29 (6) 371 (67) 2 (6) <0.001 
Supplemental data/Appendix -published online only Click here to access/download;Supplemental data/Appendix -
published online only;Ms91621 - Supplemental Tables.docx
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Active IDU (%) 11 (2) 287 (52) 4 (10) <0.001 
HIV duration (years) 12.0 (7.0-20.0) 12.0 (6.0-20.0) 19.0 (15.0-23.0) 0.979 
CD4 nadir (cells/L) 209 (95-342) 200 (100-338) 73 (49-140) 0.938 
CD4 cell count 
(cells/L) 
529 (369-732) 480 (312-691) 366 (262-596) 0.011 
HIV viral load in log10 
(units) 
1.59 (1.59-1.62) 1.59 (1.59-1.60) 1.59 (1.59-1.62) 0.003 
Undetectable HIV 
viral load  
(≤ 50 copies) (%) 
376 (75) 416 (75) 31 (84) 0.808 
Duration of ART 
(years) 
7.94 (3.72-14.6) 7.44 (3.44-14.0) 8.02 (4.10-15.8) 0.455 
Current ART use (%) 426 (85) 453 (81) 32 (87) 0.098 
NRTI 404 (81) 421 (76) 30 (80) 0.044 
NNRTI 172 (34) 101 (18) 17 (46) <0.001 
PI 197 (39) 245 (44) 17 (46) 0.134 
Integrase Inhibitors 154 (31) 177 (32) 15 (40) 0.74 
Other 31 (6) 47 (8) 1 (3) 0.195 
Exposure to 
Didanosine  
(mean years ± SD) 
0.44±1.98 0.13±1.04 
 
0.50+1.70 <0.001 
Exposure to Stavudine  
(mean years ± SD) 
0.90±2.27 0.19±1.41 1.10+2.52 <0.001 
 3 
HCV RNA pos (%) - 328 (59) - - 
Previously treated for 
HCV (%) 
- 173 (31) 
- - 
HCV genotype (%) 
       1 - 351 (63) - - 
       2 - 26 (5) - - 
       3 - 80 (14) - - 
       4 - 19 (3) - - 
       Unknown - 80 (14) - - 
Hypertension (%) 99 (20) 78 (14) 3 (8) 0.013 
Diabetes (%) 132 (26) 73 (13) 2 (6) <0.001 
International 
normalized ratio 
1.01 (0.97-1.07) 1.00 (0.94-1.05) 1.07 (1.01-1.14) 0.037 
Platelets (109/L) 205 (168-246) 200 (156-241) 156 (125-205) 0.071 
Total cholesterol 
(mmol/L) 
4.61 (3.95-5.37) 4.06 (3.47-4.64) 3.97 (3.61-4.61) <0.001 
LDL cholesterol 
(mmol/L) 
2.70 (2.19-3.35) 2.23 (1.65-2.73) 2.01 (1.33-2.83) <0.001 
HDL cholesterol 
(mmol/L) 
1.14 (0.95-1.40) 1.15 (0.95-1.39) 0.96 (0.93-1.34) 0.889 
Triglycerides (mmol/L) 1.33 (0.92-2.21) 1.25 (0.90-1.77) 1.66 (1.16-2.08) 0.103 
Creatinine (µmol/L) 83.0 (71.0-97.0) 77.0 (66.0-89.0) 83.0 (74.0-113.0) <0.001 
Insulin (pmol/L) 65.2 (43.2-112) 87.2 (54.5-162) 46.6 (41.2-90.4) 0.001 
 4 
ALT (IU/L) 25.0 (19.0-36.0) 39.0 (23.0-67.0) 30.0 (21.0-42.5) <0.001 
AST (IU/L) 24.0 (20.0-30.0) 38.0 (26.0-60.0) 31.0 (24.0-47.0) <0.001 
Total bilirubin 
(µmol/L) 
11.0 (7.4-15.0) 10.0 (7.0-18.0) 12.0 (9.0-14.4) 0.538 
Albumin (g/L) 42.0 (40.0-44.0) 41.0 (37.0-43.0) 42.0 (39.3-43.8) <0.001 
 
Legend: Continuous variables are expressed as median (IQR) and categorical variables are 
expressed as frequencies (%), unless otherwise specified. For the two-way comparison of 
HIV/HCV coinfected vs. HIV monoinfected and HIV/HBV coinfected patients, p-values were 
computed using a Fisher’s exact test for dichotomous variables, a chi-squared test for categorical 
variables, and a Wilcoxon rank-sum test for continuous variables, and are considered significant 
when below 0.05. Abbreviations; ALT, alanine aminotransferase; ART, antiretroviral therapy; 
AST, aspartate aminotransferase; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis 
C virus; HDL, high-density lipoprotein cholesterol; HIV, human immunodeficiency virus; IDU, 
injection drug use; IU, international units; LDL, low-density lipoprotein cholesterol; MSM, men 
who have sex with men; NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, 
nucleoside reverse transcriptase inhibitors; PI, Protease Inhibitors; SD, standard deviation. 
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Supplemental Table S2. Hepatocellular carcinoma screening rates in patients with at least one 
screening visit. 
 
Population 
Number of 
screening visits 
Patients with at 
least one screening 
Screening rate 
 
Whole study population 698 350 0.80 (0.74-0.86) 
Non-cirrhotic 317 205 0.62 (0.56-0.70) 
Occult cirrhosis 45 18 0.97 (0.72-1.28) 
Overt cirrhosis 224 68 1.33 (1.16-1.51) 
Non-cirrhotic portal   
hypertension 
112 59 
0.73 (0.60-0.87) 
HIV monoinfected 210 149 0.62 (0.54-0.71) 
Non-cirrhotic 157 121 0.57 (0.49-0.67) 
Occult cirrhosis 18 7 1.08 (0.66-1.66) 
Overt cirrhosis 15 8 0.87 (0.5-1.38) 
Non-cirrhotic portal   
hypertension 
20 13 0.69 (0.43-1.04) 
HIV/HCV coinfected 441 178 0.91 (0.83-1.00) 
Non-cirrhotic 148 76 0.69 (0.58-0.81) 
Occult cirrhosis 25 10 0.86 (0.57-1.25) 
Overt cirrhosis 199 57 1.38 (1.2-1.58) 
Non-cirrhotic portal   
hypertension 
69 35 0.71 (0.56-0.90) 
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Legend: Screening rates are expressed per 1 person-year with 95% confidence interval (CI). 
HCV, hepatitis C virus; HIV, human immunodeficiency virus. 
 
